All In MedTech

Device Trial Radar · NCT07871409

Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Jun 16, 2027

Study completion Sep 8, 2027

Sponsor

Lead sponsor
AmgenNot on our public-company list
Sponsor type
Industry
First posted
Oct 13, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

Conditions

  • Obesity
  • Overweight

Interventions

  • Maridebart cafraglutideDrug

    Administered subcutaneously.

  • AutoinjectorDevice

    The AI will be used by participants to self-administer SC doses of maridebart cafraglutide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home AdministrationTime frame: Weeks 12, 16, and 20
  2. Percentage of Participants Who Successfully Self-inject a Full Dose Among All Participants Who Entered the Home Self-administration Phase at Each Scheduled Home AdministrationTime frame: Weeks 12, 16, and 20

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Apex Clinical Research

    San Diego, California · Recruiting

  • Southern Clinical Research

    Miami, Florida · Recruiting

  • Research Institute of South Florida

    Miami, Florida · Recruiting

22 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.